Cargando…

A biomarker study in Peruvian males with breast cancer

BACKGROUND: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Castaneda, Carlos A, Castillo, Miluska, Bernabe, Luis A, Sanchez, Joselyn, Torres, Ebert, Suarez, Nancy, Tello, Katherine, Fuentes, Hugo, Dunstan, Jorge, De La Cruz, Miguel, Cotrina, Jose Manuel, Abugattas, Julio, Guerra, Henry, Gomez, Henry L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546657/
https://www.ncbi.nlm.nih.gov/pubmed/34733614
http://dx.doi.org/10.5306/wjco.v12.i10.926
_version_ 1784590230334996480
author Castaneda, Carlos A
Castillo, Miluska
Bernabe, Luis A
Sanchez, Joselyn
Torres, Ebert
Suarez, Nancy
Tello, Katherine
Fuentes, Hugo
Dunstan, Jorge
De La Cruz, Miguel
Cotrina, Jose Manuel
Abugattas, Julio
Guerra, Henry
Gomez, Henry L
author_facet Castaneda, Carlos A
Castillo, Miluska
Bernabe, Luis A
Sanchez, Joselyn
Torres, Ebert
Suarez, Nancy
Tello, Katherine
Fuentes, Hugo
Dunstan, Jorge
De La Cruz, Miguel
Cotrina, Jose Manuel
Abugattas, Julio
Guerra, Henry
Gomez, Henry L
author_sort Castaneda, Carlos A
collection PubMed
description BACKGROUND: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) expression, and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC. There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC. AIM: To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population. METHODS: This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018. Standard pathological features, TIL levels, MMR proteins, AR immunohistochemistry staining, and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material. Percentage of AR and estrogen receptor (ER) positive cells was additionally calculated by software after slide scanning. Statistical analyses included association tests, intraclass correlation test and Kaplan Meier overall survival curves. RESULTS: The median age was 63 years and most cases were ER-positive (85.7%), HER2 negative (87.2%), Luminal-A phenotype (60%) and clinical stage II (41.5%) among our male breast tumors. Median TIL was 10% and higher levels tended to be associated with Luminal-B phenotype and higher grade. AR-positive was found in 85.3% and was correlated with ER (intraclass index of 0.835, P < 0.001). Loss of MMR proteins was found in 15.4% and PIK3CA mutation (H1047R) in 14.3% (belonged to the Luminal-A phenotype). Loss of MMR proteins was associated with AR-negative (P = 0.018) but not with ER (P = 0.43) or TIL (P = 0.84). Early stages (P < 0.001) and lower grade (P = 0.006) were associated with longer overall survival. ER status, phenotype, AR status, TIL level, MMR protein loss nor PIK3CA mutation was not associated with survival (P > 0.05). CONCLUSION: Male BC is usually ER and AR positive, and Luminal-A. MMR loss and PIK3CA mutations are infrequent. Stage and grade predicted overall survival in our South American country population.
format Online
Article
Text
id pubmed-8546657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85466572021-11-02 A biomarker study in Peruvian males with breast cancer Castaneda, Carlos A Castillo, Miluska Bernabe, Luis A Sanchez, Joselyn Torres, Ebert Suarez, Nancy Tello, Katherine Fuentes, Hugo Dunstan, Jorge De La Cruz, Miguel Cotrina, Jose Manuel Abugattas, Julio Guerra, Henry Gomez, Henry L World J Clin Oncol Retrospective Study BACKGROUND: Breast cancer (BC) frequency in males is extremely low and tumor features vary from its female counterpart. Breast cancer clinical and pathological features differ by race in women. Tumor infiltrating lymphocyte (TIL) levels, mismatch repair (MMR) protein loss, androgen receptor (AR) expression, and PIK3CA gene mutations are predictive biomarkers of response to biological therapy in female BC. There is limited information about clinical and pathological features as well as predictive biomarkers in males of non-Caucasian races with BC. AIM: To investigate clinicopathological features and biomarkers of BC tumors in males and their prognostic value in Peruvian population. METHODS: This study looked at a single-institution series of 54 Peruvian males with invasive BC who were diagnosed from Jan 2004 to June 2018. Standard pathological features, TIL levels, MMR proteins, AR immunohistochemistry staining, and PIK3CA gene mutations were prospectively evaluated in cases with available paraffin material. Percentage of AR and estrogen receptor (ER) positive cells was additionally calculated by software after slide scanning. Statistical analyses included association tests, intraclass correlation test and Kaplan Meier overall survival curves. RESULTS: The median age was 63 years and most cases were ER-positive (85.7%), HER2 negative (87.2%), Luminal-A phenotype (60%) and clinical stage II (41.5%) among our male breast tumors. Median TIL was 10% and higher levels tended to be associated with Luminal-B phenotype and higher grade. AR-positive was found in 85.3% and was correlated with ER (intraclass index of 0.835, P < 0.001). Loss of MMR proteins was found in 15.4% and PIK3CA mutation (H1047R) in 14.3% (belonged to the Luminal-A phenotype). Loss of MMR proteins was associated with AR-negative (P = 0.018) but not with ER (P = 0.43) or TIL (P = 0.84). Early stages (P < 0.001) and lower grade (P = 0.006) were associated with longer overall survival. ER status, phenotype, AR status, TIL level, MMR protein loss nor PIK3CA mutation was not associated with survival (P > 0.05). CONCLUSION: Male BC is usually ER and AR positive, and Luminal-A. MMR loss and PIK3CA mutations are infrequent. Stage and grade predicted overall survival in our South American country population. Baishideng Publishing Group Inc 2021-10-24 2021-10-24 /pmc/articles/PMC8546657/ /pubmed/34733614 http://dx.doi.org/10.5306/wjco.v12.i10.926 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Retrospective Study
Castaneda, Carlos A
Castillo, Miluska
Bernabe, Luis A
Sanchez, Joselyn
Torres, Ebert
Suarez, Nancy
Tello, Katherine
Fuentes, Hugo
Dunstan, Jorge
De La Cruz, Miguel
Cotrina, Jose Manuel
Abugattas, Julio
Guerra, Henry
Gomez, Henry L
A biomarker study in Peruvian males with breast cancer
title A biomarker study in Peruvian males with breast cancer
title_full A biomarker study in Peruvian males with breast cancer
title_fullStr A biomarker study in Peruvian males with breast cancer
title_full_unstemmed A biomarker study in Peruvian males with breast cancer
title_short A biomarker study in Peruvian males with breast cancer
title_sort biomarker study in peruvian males with breast cancer
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546657/
https://www.ncbi.nlm.nih.gov/pubmed/34733614
http://dx.doi.org/10.5306/wjco.v12.i10.926
work_keys_str_mv AT castanedacarlosa abiomarkerstudyinperuvianmaleswithbreastcancer
AT castillomiluska abiomarkerstudyinperuvianmaleswithbreastcancer
AT bernabeluisa abiomarkerstudyinperuvianmaleswithbreastcancer
AT sanchezjoselyn abiomarkerstudyinperuvianmaleswithbreastcancer
AT torresebert abiomarkerstudyinperuvianmaleswithbreastcancer
AT suareznancy abiomarkerstudyinperuvianmaleswithbreastcancer
AT tellokatherine abiomarkerstudyinperuvianmaleswithbreastcancer
AT fuenteshugo abiomarkerstudyinperuvianmaleswithbreastcancer
AT dunstanjorge abiomarkerstudyinperuvianmaleswithbreastcancer
AT delacruzmiguel abiomarkerstudyinperuvianmaleswithbreastcancer
AT cotrinajosemanuel abiomarkerstudyinperuvianmaleswithbreastcancer
AT abugattasjulio abiomarkerstudyinperuvianmaleswithbreastcancer
AT guerrahenry abiomarkerstudyinperuvianmaleswithbreastcancer
AT gomezhenryl abiomarkerstudyinperuvianmaleswithbreastcancer
AT castanedacarlosa biomarkerstudyinperuvianmaleswithbreastcancer
AT castillomiluska biomarkerstudyinperuvianmaleswithbreastcancer
AT bernabeluisa biomarkerstudyinperuvianmaleswithbreastcancer
AT sanchezjoselyn biomarkerstudyinperuvianmaleswithbreastcancer
AT torresebert biomarkerstudyinperuvianmaleswithbreastcancer
AT suareznancy biomarkerstudyinperuvianmaleswithbreastcancer
AT tellokatherine biomarkerstudyinperuvianmaleswithbreastcancer
AT fuenteshugo biomarkerstudyinperuvianmaleswithbreastcancer
AT dunstanjorge biomarkerstudyinperuvianmaleswithbreastcancer
AT delacruzmiguel biomarkerstudyinperuvianmaleswithbreastcancer
AT cotrinajosemanuel biomarkerstudyinperuvianmaleswithbreastcancer
AT abugattasjulio biomarkerstudyinperuvianmaleswithbreastcancer
AT guerrahenry biomarkerstudyinperuvianmaleswithbreastcancer
AT gomezhenryl biomarkerstudyinperuvianmaleswithbreastcancer